TMO is in a sustained, powerful uptrend: the stock is up 28.54% over the past year and 29.58% over three months, and at $690 it sits roughly 98% of the way through its 52-week range of $435.27 to $704.00 — just 2% below the high. That positioning signals strong momentum but also limited near-term margin of safety; the stock has already done the heavy lifting, and the 31.45% max drawdown on record shows this name can correct sharply when sentiment shifts. The 52-week low of $435.27 was set in the spring, meaning the entire move has been a V-shaped recovery that has now fully retraced. Short-term momentum is positive but decelerating relative to the medium term: the 1-month gain of 6.41% trails the 3-month gain of 29.58% and the 6-month gain of 31.03%, indicating the pace of advance has cooled even as the trend remains intact. Notably, the stock is dramatically outperforming the market — relative strength versus SPY is +26.89% over three months and +13.01% over one year — and the most recent session saw a modest -0.93% pullback from $696.49 to $690.00 after touching $696.49, a potential short-term exhaustion signal near the highs. With a beta of just 0.877, TMO is roughly 12% less volatile than the market, which supports larger position sizing for risk-parity investors but also means the recent 29% three-month surge is unusually large for this low-beta name and may warrant caution. Key resistance sits at the 52-week high of $704.00; a clean breakout would confirm the uptrend and likely open a new leg higher, while support is anchored at the $435.27 low with intermediate support around the $600-620 area where the stock consolidated in late August and early September. A breakdown below $600 would break the sequence of higher lows and signal a trend reversal, whereas holding above that zone keeps the bullish structure intact.

Revenue is re-accelerating convincingly: Q2 2026 (quarter ended June 27, 2026) revenue of $11.994 billion grew 10.5% year-over-year versus $10.854 billion in Q2 2025, and the sequential progression from $11.005 billion in Q1 2026 and $12.215 billion in Q4 2025 shows a business that has moved past the stagnation of the 2024-2025 period. The Q2 2026 split of $6.823 billion in product revenue and $5.171 billion in services revenue highlights a healthy mix, with services (including CRO) now 43% of the total and providing recurring, less cyclical revenue. Trailing four-quarter revenue of roughly $46.3 billion against consensus FY estimates of $59.2 billion implies the Street expects continued acceleration, which is the central pillar of the bull case. Profitability is solid and stable: Q2 2026 net income was $1.736 billion (14.47% net margin), gross margin was 41.21%, and operating margin was 17.40%, with gross margin holding in the 40.7%-41.2% band across the last four quarters. The company is clearly profitable with a 15.12% trailing net margin and 18.20% operating margin, though the Q2 operating margin of 17.40% was slightly below Q4 2025's 18.85%, reflecting the dilutive effect of recent acquisitions and modest inflation. EPS of $4.68 in Q2 2026 versus $4.28 in Q2 2025 represents 9.3% growth, and the consensus FY EPS estimate of $37.35 implies continued mid-teens earnings expansion. The balance sheet is investment-grade quality: debt-to-equity of 0.737, current ratio of 1.89, and trailing free cash flow of $7.318 billion against a $217.9 billion market cap (3.4% FCF yield). Q2 2026 operating cash flow of $2.125 billion funded $450 million of capex and $1.0 billion of buybacks, while Q1 2026 saw $8.872 billion of acquisitions and $3.0 billion of repurchases funded partly by $4.215 billion of debt repayment activity — an aggressive but manageable capital allocation posture. ROE of 12.61% and ROA of 5.13% are respectable for a capital-intensive instruments business, and the interest coverage ratio of roughly 5.2x leaves adequate cushion.